The Hellenic Atherosclerosis Society guidelines for dyslipidemia management, 2023

Recommendations for management of dyslipidemia in patients with chronic kidney disease (CKD):

• Stage 3 CKD (eGFR 30–59 mL/min/1.73 m²): These patients are at high risk. Recommend LDL-C reduction by ≥50% from baseline, targeting LDL-C below 70 mg/dL (1.8 mmol/L). (Class I)
• Stage 4-5 CKD (eGFR <30 mL/min/1.73 m²): These patients are at very high risk.  Aim for LDL-C reduction of ≥50% from baseline, with an LDL-C target below 55 mg/dL (1.4 mmol/L). (Class I)
• Non-dialysis-dependent CKD patients: Statin or statin/ezetimibe combination therapy is indicated. (Class I)
• Dialysis patients on lipid-lowering therapy: For those already taking statins, ezetimibe, or a statin/ezetimibe combination at dialysis initiation, continuing treatment is advised. (Class IIa)
• Dialysis-dependent CKD patients without ASCVD: Starting statin therapy is not recommended. (Class III)
• •Kidney transplant recipients: Statin therapy is recommended for consideration. (Class II)

Source: Katsiki N, Filippatos T, Vlachopoulos C, et al. Atheroscler Plus. 2024;55:74-92. Published 2024 Feb 17. doi:10.1016/j.athplu.2024.01.004